ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,213.49
0.51%
Dow Jones
38,675.68
1.18%
Gold vs US Dollar
2,302.57
0.00%
Brent Oil
82.765
0.00%
Bitcoin
63,177.12
0.46%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) News

AstraZeneca (AZN)

AstraZeneca PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AZN
DateTimeSourceHeadlineSymbolCompany
02/05/202412:00Business WireCALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trialNASDAQ:AZNAstraZeneca PLC
01/05/202412:05Business WireAstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolioNASDAQ:AZNAstraZeneca PLC
29/04/202412:00Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralowNASDAQ:AZNAstraZeneca PLC
25/04/202413:00PR Newswire (US)AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:AZNAstraZeneca PLC
25/04/202412:53IH Market NewsU.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy ForecastNASDAQ:AZNAstraZeneca PLC
25/04/202412:52IH Market NewsSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on EarningsNASDAQ:AZNAstraZeneca PLC
25/04/202407:00Business WireQ1 2024 resultsNASDAQ:AZNAstraZeneca PLC
16/04/202412:00Business WireIMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trialNASDAQ:AZNAstraZeneca PLC
12/04/202412:05IH Market NewsParamount Global Board Shrinks, Morgan Stanley Faces Regulatory Probe, and More NewsNASDAQ:AZNAstraZeneca PLC
11/04/202412:24IH Market NewsCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More NewsNASDAQ:AZNAstraZeneca PLC
11/04/202412:00Business WireFASENRA approved for treatment of children aged 6 to 11 with severe asthmaNASDAQ:AZNAstraZeneca PLC
06/04/202404:10Business WireENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid TumorsNASDAQ:AZNAstraZeneca PLC
06/04/202402:43Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumorsNASDAQ:AZNAstraZeneca PLC
05/04/202412:00Business WireIMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trialNASDAQ:AZNAstraZeneca PLC
02/04/202412:00Business WireDatopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancerNASDAQ:AZNAstraZeneca PLC
02/04/202407:00Business WireDatopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast CancerNASDAQ:AZNAstraZeneca PLC
01/04/202412:00Business WireVOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNHNASDAQ:AZNAstraZeneca PLC
27/03/202410:54IH Market NewsGameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More NewsNASDAQ:AZNAstraZeneca PLC
26/03/202411:20IH Market NewsSuper Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest NewsNASDAQ:AZNAstraZeneca PLC
25/03/202411:00Business WireULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)NASDAQ:AZNAstraZeneca PLC
19/03/202411:33IH Market NewsUnilever Initiates Ice Cream Division Spin-Off and Announces Job Cuts; Berkshire Ramps Up Share Buyback Efforts, and MoreNASDAQ:AZNAstraZeneca PLC
19/03/202411:00Business WireAstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancerNASDAQ:AZNAstraZeneca PLC
19/03/202410:52IH Market NewsAstraZeneca to acquire Fusion for $2 billionNASDAQ:AZNAstraZeneca PLC
18/03/202411:00Business WireAstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolioNASDAQ:AZNAstraZeneca PLC
14/03/202411:39IH Market NewsFisker’s Shares Take a Hit Amid Speculation of Bankruptcy, Altria Divests from AB InBev to Fund Stock Repurchase InitiativeNASDAQ:AZNAstraZeneca PLC
13/03/202411:06Business WireAstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPDNASDAQ:AZNAstraZeneca PLC
07/03/202410:43IH Market NewsTesla Exits Market Top 10, Victoria’s Secret Stock Tumbles 30% on Weak ForecastNASDAQ:AZNAstraZeneca PLC
26/02/202421:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
26/02/202414:00PR Newswire (Canada)Alexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE CampaignNASDAQ:AZNAstraZeneca PLC
26/02/202414:00PR Newswire (Canada)Alexion Canada donne de la couleur aux maladies rares avec la campagne internationale colourUp4RARENASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN

Your Recent History

LSE
SCLP
Scancell
LSE
AGL
Angle
LSE
FUM
Futura Medical
LSE
AAU
Ariana Resources
LSE
GFM
Griffin Mining
LSE
PHNX
Phoenix
LSE
SCE
Surface Transforms
LSE
HARL
Harland & Wolff
LSE
TERN
Tern
LSE
GKP
Gulf Keystone Petroleum
LSE
EEE
Empire Metals
LSE
BEN
Bens Creek
LSE
AAZ
Anglo Asian Mining
LSE
ANGS
Angus Energy
LSE
JEMA
Jpmorgan Emerging Europe...
LSE
YU.
Yu
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved